Thứ Ba, 15 tháng 1, 2019

Youtube daily Jan 15 2019

Chris Hill: Before we get out of here, give me one reckless prediction for 2019.

Andy Cross: We talked a little bit about the FAANGs. I mentioned Facebook.

I think Facebook ends up profitable for the year. Reckless prediction here, of course.

Not investing in Facebook.

I own shares, not investing just for one year, bought the stock around $140.

Really hit some struggles.

We've talked a lot about them over the year on the show here and written a lot about them.

I think that stock rebounds a little bit in 2019, continuing to figure out how to

better solve the challenges they're having. I think they're not done. They have some work to go.

Also, from a reckless prediction side, I would be surprised if Sheryl Sandberg is not there

by the end of the year.

Hill: I think you buried the lede. That's the more surprising thing.

Cross: Could be. It's not my stronger reckless prediction of the two.

I think Facebook sees a little bit of a rebound. I think they get some things right.

They've hit these struggles and had some culture clashes internally.

That's been a struggle. I think they get that worked out this year.

Can I go with a non-financial, non-stock reckless prediction for you, Chris?

Hill: Absolutely!

Cross: I think Ireland wins the World Cup of rugby played in Japan this fall.

They take down the All Blacks in New Zealand. They had a great 2018.

I think they have a shot to dethrone the All Blacks in New Zealand at the Rugby World Cup

held in Japan this fall. Hill: I would love to see that.

I can also think of a couple of listeners that we have in New Zealand who are very angry right now.

Cross: Listen, they're a phenomenal team! They're like the Patriots. This is why it's reckless.

Last year was great for them in rugby.

Hill: In the wake of last night's college championship game, I thought we were going

to make a prediction about the University of Michigan.

Cross: [laughs] I went there, man. I don't know if Harbaugh's there by the end of the year.

I don't know that. But I was not ready to make that prediction.

Listen, my wife, with Urban Meyer leaving OSU, she said, "Hey, maybe you have a shot

to actually beat Ohio State this year."

I was going to make that my reckless prediction, but I didn't go there.

Hill: Somewhere, there's an offshore betting outlet that has a pairs bet that they've just created.

It's basically, who lasts longer in 2019 in their current place of employment:

Jim Harbaugh or Sheryl Sandberg.

Cross: True!

Hill: Let's bring in our man behind the glass, Dan Boyd. Dan?

Dan Boyd: Andy, I love your enthusiasm about the Irish rugby team, but I just want to say,

I don't think it's a reckless prediction to predict that the winner of the Six Nations Cup in 2018

is going to win the Rugby World in 2019. I don't consider that reckless.

Cross: I don't know, I think the gap between New Zealand and the rest of the world is still pretty high.

I'll disagree with you on that.

But thanks for the call! Boyd: That's like saying, "The No. 1 and

No. 2 teams are playing in the Super Bowl. I think the No. 2 team is going to win."

Real reckless, Andy! Cross: I don't know, man!

Nobody thought the Eagles were going to win the Super Bowl last year!

Hill: There you go.

Although, I will point out, Dan does have experience as a college rugger.

Cross: He may know better than me.

I'm just excited to see if they can take down the All Blacks.

For more infomation >> Will Facebook Stock Recover in 2019? - Duration: 3:40.

-------------------------------------------

Great Life Advice for Kids: Start Investing Young - Duration: 54:28.

David Gardner: I can't think of a better way to start the new year than surrounded by friends,

talking about something fun, and ultimately even more so important, and then sharing it out.

At what age did you start investing?

There's no right answer.

We all have a different story to tell, but at what age did you start investing?

And no matter what age you did, you now have an opportunity to start someone else out even

earlier and even better. But how?

Do you feel equipped? Well, that's what we're here for.

Get your kids started investing to start the new year with Rule Breaker Investing.

Gardner: And welcome back to Rule Breaker Investing!

Happy New Year! What a delight it is to have you join us.

This is the second straight podcast -- this is a new record for this podcast --

where we've had no sponsor, and I guess the implication is sponsors aren't showing up because they think

people won't listen to podcasts on Christmas Day or New Year's Day.

It doesn't make any sense, but I'm happy to say it's made sense to you.

And because we're doing this podcast in part timelessly -- I hope many of us are hearing

this podcast, even though it happens to be New Year's for 2019 -- I hope that you'll

enjoy this conversation that I'm having, as I mentioned earlier, on a topic most important

to us with a fun group of Fools to help you get somebody else [somebody younger than you] started investing.

I have a friend named Bernard Wright here in Washington, D.C.

Bernard came up to me and he said, "Hey David, could you do a podcast on this topic?"

His son is a Marine, so that's not a newborn.

We're going to talk about newborns, but we're also going to talk about college grads.

We're going to talk about people who are younger than us and helping trigger that person, catalyze,

switch him on, and get him started investing.

That's really our focus, and I do want to throw out some credit to one of our listeners

because Robert Trapp on our mailbag two months ago said, "I now have eight grandchildren,"

Mr. Trapp wrote, "ranging in age from one to 13 years old.

I want to begin teaching them about investing.

I'm thinking that a good way to begin is set up a custodial account with the brokerage

firm I use, which happens to be Schwab. "What do you and your panel of Fools think?

Do I make all of their individual stock holdings identical?

Shall I work with the older children to help them choose their own portfolios?

How do I give stocks to them?

What are the tax implications of custodial accounts for minor children?

Thank you for all you do in the name of Foolish learning." Signed, Robert Trapp.

I told Mr. Trapp a couple of months ago, "Darn it!

We're going to start off the year 2019, timelessly going forward, with answers to those questions."

Now whether we hit each of those, Mr. Trapp and my good friend Bernard; whether we hit

everything that you're hoping we talk about, we probably won't.

But I'll say this. I've brought a wonderful group of Fools.

They'll introduce themselves as they enter into the conversation to talk about getting started investing.

So, yeah! That's the purpose of this podcast and really, in large part, that's the purpose of The Motley Fool,

now in its 26th year of operation.

That's why we're doing this and before I introduce my first guest, Jason Moser, I want to mention that

if you enjoy this podcast, "Getting Others Started Investing," you might want to listen

back to "Get Started Investing," for yourself, because we did a two-part series toward the

end of last year.

The first one was on October 3rd of 2018, so point your iTunes player or Google Play,

Spotify, or however you like to listen to Motley Fool podcasts at Rule Breaker Investing

the first week of October.

And then the first week of November, which was part two where we answered your questions

aroused by the first podcast.

So that's a little two-part series for getting anybody started investing, but the real purpose

of this conversation, Jason, is to get people younger than we are [not just us, but others] started investing.

And I want to start with you because you've often talked about how you got your daughters started investing.

Let me start because I'm hoping for a little bit of a chronological swing to this conversation.

We're going to start with getting young -- like really young -- like maybe newborns starte d,

and then get through to the Marine Corps grads of our lives.

Jason, did you start with your daughters at age zero, one, 12?

How did it start? Jason Moser: I like that idea.

Let's start with the chronology. There's no better place than when [they're newborns].

I still remember pretty well when my kids were born.

I have two daughters, 12 and 13 years old now [almost 14, I guess, at this point].

It all goes back to what the ultimate goal is, because even if we're talking about investing

for kids, there's still a goal in mind, whatever your goal is.

If we're adults and we're investing, typically that's because we want to fund our retirement.

What's the goal for the child?

As soon as they were born, my wife and I were both onboard with making sure we had some

way to get some money saved up for them for college down the road with the understanding

that that's not getting any cheaper and also

understanding that time really is the investor's best friend.

Our goal, in that regard, was to get a nest egg started for higher education when that times comes.

Right when they were born, David [I think we got their Social Security numbers the next day],

I opened up 529 accounts for both girls immediately.

We funded those accounts with just an initial $500 and then set it up so that every month

there was an automatic deposit [a very minimal automatic deposit] that goes into each 529.

It's not something that we even really feel.

I know that we're very lucky that my wife and I both have jobs that can help fund that.

The point is that for every month of their lives [from this point until they reach college age]

they're going to have a small monthly deposit that goes into that 529.

What we've seen over the course of time of 12 and 13 years is it's pretty amazing what

just a little bit every month can do.

And we talk a lot about the magic of compound annual growth and it really is magic,

and the longer it goes the more magical it seems.

For our purposes with newborns, the goal was to fund higher education.

That's how we got them started. Gardner: That's great, Jason.

So with that goal orientation and really starting as early as possible, you got a great head start

on their behalf when they were born.

It's interesting because we all have probably different approaches and that's part of what

we're going to reflect. We're going to reflect some motley to what we're doing.

But for us, also with kids, I just started them with custodial accounts.

It wasn't toward 529.

And I have to say, in some sloppy ways I'm sorry to say we never really did 529 plans in our family.

Both of these are definitely ways to save for kids and get them started investing,

and I know a lot of your journey and your story, Jason [and we'll get there a little later],

are what to say to kids once they're of age. The conversations we have.

The culture that we create around our families.

But Naima Barnes, you're part of our conversation, today.

You have a deeper understanding of these kinds of types of accounts and some of the reasons

behind them, so I wanted to turn to you next and just ask you to introduce yourself briefly

and then let's get some of the nuts and bolts, there, of how to actually get kids started

investing when they're too young to even know themselves.

Naima Barnes: My name is Naima. I work in Motley Fool Wealth Management

as a paraplanner. There's two main types of custodial accounts.

Both came from different laws that were put in place a while ago.

One is the Uniform Transfers to Minors Act, also known as the UTMA.

The other is the Uniform Gift to Minors Act, also known as the UGMA.

Gardner: I think I did a UGMA -- an u-h-g-m-a-h. I think I did.

Sometimes people think that surely David Gardner or Tom Gardner, the co-founders of The Motley Fool,

would know everything about money, but the truth is I hope Tom and I are constantly

letting people know we don't know that much, and so this is something I didn't even realize.

What's the difference between those two things?

Barnes: The difference is that with one of the accounts, the UGMA, if I'm not mistaken,

you can [include] real estate. I'm looking at Bro to confirm.

Robert Brokamp: Yes.

This is Robert Brokamp of the Motley Fool Answers podcast and the Rule Your Retirement

and Total Income services. It really depends on which state you're in.

That determines which one you'll be opening up.

The basic point is that minors can't own investment accounts, so it has to be a custodial account

with an adult's name on it and your state will determine which one you open up.

Barnes: And then from there Grandma or Grandpa or a guardian or parent are going to open

that account for their newborn or anyone up to the age of majority, which depending on

your state could be 18, 19, or if they're in college 24.

Then they'll be able to purchase, if they please, individual stocks, real estate, [or] bonds.

With a 529, normally you're utilizing funds that the 529 custodian is going to say if it's available.

Gardner: So 529 plans are directed toward an educational outcome, as Jason was mentioning earlier.

We've covered UTMA, UGMA, 529s.

Are there other accounts that we should be thinking about as parents or mentors,

or do those pretty much capture it? Barnes: Those are the big ones.

Also, a parent can open a Roth IRA for a child, but that is if you have earned income.

So if your child has a summer job and they make the IRA limit amount, which varies on

the year, then they can contribute that much for them. You can also use a Coverdell account.

With those usually the maximum that you can contribute is lower than that of a 529 or

an UGMA/ UTMA. The gifting maximum for those varies depending on the year.

Gardner: So Naima, I'm hearing you describe these different accounts and I'm trying to

put myself in the seat of our listener. We've done a good job talking about the possibilities.

How do you open one of these?

Barnes: There's a bunch of different custodians you can use.

You can go to places like Charles Schwab or Fidelity.

You can also look at strictly online brokers like E-Trade and Ally Invest.

Robinhood is really popular, but Robinhood at this time doesn't offer custodial accounts.

They only offer individual accounts.

I did find out that Stash, which is another app that you can use, offers custodial accounts

so you can begin saving for a child on their online platform.

Brokamp: As you listen to all this, you might be wondering which one you choose, and I would

say it starts with [the goal you have for the money].

If you want to teach your kid about investing while also saving for college, the 529 and

the Coverdell are the way to go.

The big difference, there, is with the Coverdell you can buy individual stocks and with the 529 you can't.

I think that would influence it.

But if you're trying to get your kids started with a nest egg that they can control for decades,

then I would look at the custodial or the Roth. The Roth is better if they have the earned income.

We opened a Roth for my teenage son after he started a job as a lifeguard.

But if they don't have earned income, you've got to go with the custodial.

The drawback to that is once they reach the age of majority, it's their money.

Barnes: So they can buy a sports car if they want.

Brokamp: They can do whatever they want with it, and from a financial aid perspective,

if you're looking that far down the road for college, having money in a Coverdell or a

529 is better than in a custodial account. So that's something you want to factor into that, as well.

But if you're looking to really get the kid started and have them take over the portfolio someday,

I would say the custodial or the IRA is the way to go.

Gardner: That's really interesting. Each of us can think back to when we did startinvesting.

As I asked at the top of the show, some of us did so as adults.

Some of us did so as kids. I had a dad who did the Uniform Gift to Minors Act account.

We were trusted with the money that was invested for us and I'm really grateful because in

some ways it became the seed capital for The Motley Fool.

I'm deeply grateful for that. I will say I did buy a sports car.

Sports cars were cheaper back then.

Sports cars were much cheaper and also [a humble brag, here] I had a full scholarship

to college so my dad was happy and was probably OK with me spending some of that on a car.

Before we move into the middle years where we're talking to kids who can understand and

respond back; and what we should say and how we should train them, you do want to think

about playing it forward. What's the right cultural answer?

Not for our culture but for your culture. Your family.

For our family, we raised them in an environment of trust, which may sound very wholesome.

It hurts a lot sometimes. It's not always right for everybody.

It was right for me as a kid and then it's what I did for our kids.

I also had them with the UGMA account, which we could add to.

It could be stocks and all the way through, but the wills and estates guy that we consulted

with 10 years ago was saying things like, "I'd never do that. I don't trust my kids."

Indeed, he was probably right.

We all have a different culture that we come from, and some overlap, so there's a philosophical question.

Before we proceed forward into kids who are eight, or 10, 12, does anybody want to add

anything along those lines? Have we really tied a bow on starting newborns?

I hope we have for our listeners, but anything more to add before we advance?

Barnes: Just a note. It doesn't have to be a parent that starts a 529 account.

I started one for my brother because I wanted to make sure that when he went to college

if he needed a new laptop or some books that he would be able to have that.

Gardner: That is awesome! Brokamp: That is very thoughtful.

Gardner: Naima, I needed you as my sister. I love my sister, but that's really loving.

Barnes: Now, don't get me wrong.

I have two other sisters, so they probably will hear this and will not be too happy.

Gardner: Just don't tell them that you were on this Rule Breaker Investing podcast.

Just don't tell them. Barnes: They also did get scholarships, though.

Gardner: That's pretty great. Good for them. So we've talked about types of accounts.

We've talked about it being as simple as, in Mr. Trapp's case [the man who triggered

this podcast] he's got Schwab so he could just start talking with his Schwab representative

and surely that will work. But maybe a question to the group, here, about amounts.

Can you add on a regular basis? How much should you start it with?

Any thoughts from the panel about that?

Moser: I'll go back to the word that I used from the very start and that's the "goal."

We were not trying to accomplish, in setting up these 529s, being able to pay for everything.

My wife and I would like our kids to have some skin in the game and figure out a way

to get grants, or scholarships, or work during school.

Gardner: Scraps.

Moser: We wanted them to have a little ownership. The goal wasn't really to fund their entire education.

With that in mind, $500 seemed like a reasonable number to get the account opened.

I don't know why. I just picked it arbitrarily.

And then from there, I think you can set that monthly deposit to whatever you're comfortable with,

whether it's $10 or $100. I think the key is to just get it going immediately.

That compound annual growth is just the most phenomenal thing, and the longer you have

a chance to let it work for you, the better off you're going to be.

Daniel Masseca: I'm Daniel. I'm a financial planner with Motley Fool Wealth Management.

We have a newborn. She's six months old...

Gardner: Congratulations! Moser: Congratulations!

Brokamp: Congratulations!

Masseca: We also started with a 529 and figured that was the best way to go considering our goals.

We front-loaded it a little bit, because we're in a position to do that now and don't know

what the future holds for us.

To take advantage of that compounding we figured we'd put as much as we could in today knowing

that we may have conflicting goals in the future. We'd know that we took care of that to start with.

Gardner: I'm glad you just jumped in, Daniel. For our listeners, this is our full panel, now.

Just to make sure it's clear I have Naima Barnes, Daniel Masseca, Robert Brokamp,

and Jason Moser joining with me, so we have five voices that you're hearing from five different perspectives.

Daniel, congratulations! Did you get a little paternity leave from The Motley Fool?

Masseca: I got plenty of paternity leave. Gardner: I'm glad to hear that.

Masseca: More than I wanted!

Gardner: That's a really important thing that we figured out a few years ago at The Motley Fool.

We weren't doing that 25 years ago, but we've definitely been doing that for some years.

Robert, you and I are old hands, here, at The Motley Fool.

Brokamp: I know. Gardner: Do you remember your paternity leave?

Brokamp: I did not get paternity leave. Gardner: I didn't either.

Brokamp: But we have such a flexible workplace that it worked out OK.

Gardner: I keep wanting to jump it forward and talk about how to talk with kids about

stocks and we are going to get there, but going back to one more thought, here,

which is about the goal that Jason started us off with.

I do remember the Uniform Gift to Minors Act account, the custodial account I was given

that my father, in this case, decided what age I would get that.

That's a choice, too, and that's a little bit more about philosophy and I'll just talk

briefly about how I changed it up for my kids. I received my account at the age of 18.

I'm glad that I got started that young. It was responsibility for me.

It wasn't enough that I was going to be retiring, but it was enough that I didn't have to

run out and get a job right after college. And I was managing that account during my college days.

It was arguably a little distracting.

I was not a trader, by any stretch of the imagination, so it's not like I was highly distracted.

But as I thought about what I wanted to do for my kids, I decided I wanted to make it 21 for them.

I think there are different ages that we can choose for those accounts and so for me, anyway,

or for the Gardner kids, when they turn 21 they get theirs.

Again, more toward that goal orientation.

More toward trying to make the best call for you and your family or your situation and

not expecting a cookie-cutter answer from our talented panel.

So if there are three chapters in this conversation, that's the end of chapter one; chapter one

getting newborns, getting Daniel's six-month-old going on the 529 plan when kids don't even

know what you're doing for them and how you get that started.

And darn it, it's so busy, our lives, especially these young parents having to do all the other

things that this feels like yet another.

But darn it, we hope you'll prioritize that because when you think backward from the future,

this is one of the most important things you can do.

It's good to send thank you notes for gifts at baby showers and these kinds of things,

but I would suggest that this will stand the test of time in a more powerful way.

So we hope, with this podcast, you'll start to prioritize that if you weren't already before.

Chapter two is the child who is eight, 10, 12. He or she can recognize, now, what you're doing.

They're starting to learn about the world.

How do we talk about investing money -- maybe even business -- with kids?

Daniel Masseca, we were chatting by Slack which is, by the way, not sponsoring this podcast.

This podcast is not brought to you by Slack because nobody would pay us for this podcast this go-round.

But we were chatting briefly on Slack before this episode and you were mentioning a story

of how you got started at the age of eight by your grandmother.

Masseca: Yes, my first memory of investing was when I was eight years old and my grandmother

asked me a question.

She said, "If you could own any business in the world, which one would it be?"

And being eight years old and I wanted to rule everything, I thought of the largest

business I could think of and that was Coca-Cola, a product I saw everywhere, every day.

So she bought shares of Coca-Cola for me and taught me what it meant to be a business owner

and let me know that I was now actually a part owner of that company.

I was very proud of that and learned how to look up the ticker symbol in the newspaper.

I'd track what was going on much like a kid would do with baseball statistics;

and went about my life feeling vested in that company.

Gardner: That's incredible! What a great gift from Grandma!

Masseca: It really was.

I think it was really important to her that I understand what owning shares of stock meant.

She did the same for my brother. He picked McDonald's.

Both turned out to be really good choices, by the way. I was an investor ever since in an UGMA account.

I invested money that eventually helped pay for my wedding and my house.

I even remember as a kid going to Atlanta to the Coca-Cola factory and thought it would

be very important for them to know that I was a shareholder and I would get some special treatment.

Gardner: Love it!

Masseca: But I think that really set me on the right trajectory and because of that

I knew what it meant to be an investor.

Gardner: Let's be analytical in a way that's almost unfair to a lovely story from one's

childhood full of nostalgia and prosperity. Let's be a little analytical getting underneath that.

What one, two, or three things was she doing that I can hear and then put into play in

conversations I might have with an eight-year-old?

Masseca: Pride of ownership, so know what a stock is, because a stock is a very conceptual

thing unless you know you're owning a company. At its core that's what you're buying.

The second issue is building passion. She made sure I picked something that I was excited about.

Thankfully it was publicly traded and she could buy shares.

And then she got me engaged.

So learning how to look it up, which is easier these days, was something I could continually do

that made it a part of my life and made it a habit.

Gardner: Did anybody have a similar experience as a child, themselves, or a highly contrasting experience?

Brokamp: I was not quite a child -- I was more of a recent college grad -- but I had

a very similar experience, at least related to Coke.

Just hearing someone tell me, "You can buy that Coke, drink it, throw it away, and then

you have nothing to show for it.

Or you can buy part of the company and five, 10, or 15 years down the road it will be worth

more than you spent."

Masseca: So along that same vein, a few years ago a much younger brother-in-law had a ton of video games.

It was his birthday and, for better or worse, I really didn't want to buy him another video game

but felt it would be meaningful to buy him shares of Activision...

Gardner: Nice! Masseca: … and thought let's

get him down the same track that I was.

I thought he probably wouldn't care about it at all, but he was actually very excited

to see that he owned shares of Activision, which was putting out a lot of the games he was playing.

I think it was the same thing.

He could have a game, or [he could be a part owner of] this thing on which he spends a

lot of money and hopefully build some wealth.

Gardner: And I see a lot of heads nodding around this table because we all feel that, I think.

There's no better feeling, really, than feeling like every dollar you're throwing at a company

you're actually going to make even more than that back by owning its stock.

That's true of some of the great consumer companies of our time and we just named some of them.

Moser: I've got a pantry full of McCormick and it seems like every dinner has some McCormick

product involved.

Gardner: Jason, do you sometimes open the cabinet and just gaze?

Moser: I look at it and I just beam with pride.

Gardner: And you won't say this to anybody else in your family, but quietly.

Moser: One of my favorite businesses in the world.

Listeners to the Market Foolery and Motley Fool Money know I'll talk about that company

all day if I get the chance.

Gardner: It's been a great performer for Stock Advisor, among other companies.

Moser: A wonderful business.

Gardner: So it is that experience of the product or service for a lot of middle-school-aged children.

I think it's a very appropriate time to talk with kids about that.

They know the world well enough, and so really what you're doing is you're hooking in this

entire financial component to the world that they're otherwise seeing and you're

letting them know, switching them on, that you can be making money at this thing that you love, as well.

One part of it might be showing them where that stock was 10 year ago, whether it's Disney,

or Coca-Cola, or McDonald's, or Activision Blizzard.

Another part of it is just making them more active observers of that company going forward.

Beyond just the pride that Daniel mentioned, you also talked about your grandmother giving you

an awareness and an interest. In fact, you pushed it further, Daniel.

You said that she taught you something about business.

Was she an entrepreneur herself?

That's such an important thing for us here at The Fool -- that it's not just about the markets.

It's as much about the businesses themselves and connecting those things.

Masseca: Yes. She is an entrepreneur.

She ran an antique gallery back in South Africa where she's from.

She runs a real estate practice now and I think that probably imparted some entrepreneurial

spirit in me that I still have today -- getting involved at such a young age with that

kind of understanding and excitement.

Gardner: Just to stick with the chronology that we've been shaping -- the narrative of

the newborn to the middle child -- one thing we hope our listeners are inspired to do is

to start that account early. And that's kind of the nuts and bolts.

That's blocking out the time. Having the conversation with the financial representative.

Getting the account funded.

But really from that point on, it's as much about the conversations we have and the culture

that you raise that child in, and I want to talk briefly about that.

Certainly, one thing that we all love, here, at The Motley Fool [you're not required to

feel this way to be hired here, but I bet you often do it automatically], is that you love business.

You think it's amazing that we have these trades.

You're good at this and I'm good at this, so I'll buy from you and you buy from me,

and it's a much better world when I'm getting your best, and you're getting my best, and

we're trading back and forth. So there's a lot of positivity to that.

There's a lot of optimism to thinking that the world will get better.

I think that it has in so many ways.

Of course, never perfectly and sometimes worse in different contexts.

But for the most part, look at a graph of the Dow Jones Industrial Average over the last century.

It starts in the lower left and it goes to the upper right and that's our expectation

over the next century.

Given that, I feel like we're talking a lot about the do's -- do this, do that.

Does anybody have a "don't" that's on their mind?

Something that didn't work for you either as a young person growing up or with young

people that you're associated with?

Brokamp: I have, anecdotally, heard stories of people saying, "My kid loved this company,

so I bought that one stock and that one stock didn't do well, so therefore..."

Gardner: GoPro! GoPro! They loved the GoPro!

Brokamp: Exactly. Pets.com. "Oh, my kids love pets. We'll get Pets.com."

It didn't work out, and that's the wrong way.

I mean, every kid should learn that stocks do go down and some do go out of business.

So what's we've done for my kids is they've been allowed to choose stocks, but we have

also had index funds [both US S&P 500 and international] so that they understand the ups and downs.

It's just the overall stock market as well as understanding the ups and downs of individual companies.

Barnes: And with an index fund you're able to get exposure to a bit more than maybe one

share of Amazon if you can swing that, so not all of your eggs are in one basket.

You have some exposure to maybe 500 companies if you're in an S&P index.

Gardner: I have to admit.

There is a strong bias -- not even an unconscious one on this podcast -- about owning stocks

and loving stocks, but certainly I know, Naima and Daniel, you both, in particular, are probably

every day fielding questions and having conversations that are

far more often about funds than about stocks themselves.

Masseca: That's true.

And earlier you asked about amounts, and I think that speaks directly to your goal for

helping someone get started.

If you are trying to teach a child about investing, you probably wouldn't want to give them access

to everybody you've been saving and tell them to invest it.

So maybe putting a smaller amount in the individual stocks they're passionate about and the rest

in something like an index fund or a more-widely diversified pool of stocks may make a lot of sense.

Moser: And I think framing it up from the very beginning that expectations are realistic.

We have brokerage accounts for each daughter, as well, where they are able to add individual stocks.

Gardner: I was wondering about that, Jason, because you've mentioned picking stocks with them,

but then you were saying 529, so I was thinking...

Moser: They do have both, actually. Gardner: Yes, that's great.

Moser: Perhaps we can get into that story, as well, but my main point being in framing

the expectations from the very get-go and saying, "Look, you're going to have this account.

You're going to have this portfolio. You're going to own shares of 12 different companies.

They're not all going to be winners.

As a matter of fact, probably four of them are going to be losers, and that's just the name of the game."

It's not about batting a thousand.

It's about finding some great businesses -- investing in a lot of different businesses -- and chances

are that the math will work out where you get some good winners, and when you get some

really good winners, they can just keep going up and up when really the down side is capped

at zero for virtually any individual investment.

I think framing the expectations appropriately from the beginning helps particularly

when they're kids in understanding what they're actually trying to do.

Barnes: And this helps to teach them to be long-term investors, because they may see

that one of their stocks went down so they want to get out.

Or [we've] had those conversations of, "Let's wait and see how it does over this period of time."

Moser: Definitely. I think

starting at that age, there is this added benefit where they're only so interested in it

until they want to actually go play a video game or talk with their friends.

It's not like we're sitting at the dinner table, every night, talking about their portfolios.

We'll probably check in maybe once a quarter and say, "Hey, look, there's your Apple stock.

You've owned that since 2013. It's up 150%. But oh, look.

You've got TripAdvisor there, too, and that one's still down.

But you've got this big portfolio of 12 stocks now, and it looks like you're doing OK."

Then they want to go off and do something else.

The benefit, there, is that at that age they're only so interested in it.

They don't want to talk about it all the time.

And when it's not something that's at the top of their minds, they're certainly not saying,

"Oh man, I really ought to sell that TripAdvisor position because it's obviously a loser."

And as time goes on, they do see the benefit of ignoring it and letting it take its course,

as some of those losers can turn out to be winners after all.

Gardner: Certainly one of the recurring themes of this podcast is a love of games.

I'm curious if anybody else had the experience I did, which is I first got excited by the

stock market not by my parents, but by a fourth grade contest that Mr. Hoskinson at St. Albans School

in Washington, D.C. ran for us, where we each were supposed to pick 10 stocks.

We typed them in and kept up.

It wasn't even that we typed them into a computer, because this is quite a long time ago,

so it was more like a typewriter. Maybe handwritten.

But as much of the game was about looking in the newspaper for the stock quotes and

writing them down and doing some math, so it was as much about math.

But I did something that I think a lot of my fellow classmates did.

I went home, let my parents pick my stocks for me, and as it turns out, my dad, in particular,

distinguished himself and I won the contest about three months later which, by the way,

we all know three months doesn't tell a lot.

And that was incredibly lucky that as a reward I got this oversized [I can still see it] Hershey Bar.

I think it might have been with almonds.

You know how you have $25,000 checks that are bigger than four people?

Well, that's how that candy bar looks to me today, years later.

So I think for kids who enjoy games [at least that was true for me], gaming it up.

Making it a little bit of a competition.

Maybe a family competition or just the math of it could also speak to some kids.

Moser: If you recall, speaking of gamifying it and combining the gamifying and the media

part of it, my daughters, not all that long ago, were part of a Supernova exploration...

Gardner: Ah, yes, Jason...

Moser: … and they helped participate in whittling down the four companies to one eventual winner.

I believe that winner was Hasbro. My daughters were thrilled.

They own shares themselves...

Gardner: Wonderful! Moser: … and that really, I think, lit the fire in them.

Even now they are telling me that they want to intern, here, when they're old enough and

then they want to get a job here. So thank you, David!

You've offered some financial security for generations to come.

Gardner: I think you're doing a little bit more than I am, for them, in that regard,

but thank you, Jason! Thank you for that reminder!

So yes, not everybody's going to have the opportunity the Moser girls have hanging out

at Fool HQ, but anybody can make it fun for a child.

Anybody can game it up.

Not everybody loves games, but if your kids do, then yes, there's things like fantasy football.

There are fun mobile app games.

But the stock market and following stocks -- and maybe having a competition with the

cousins or the parents, or a family thing -- we're here at the start of a new year.

In a sense every day is the start of the next 365 days.

So you could kick off a little competition and that might speak to a child.

Before we go to chapter three, which is going to be twisting the arm of a high school or

college grad to get them started, I wanted to ask just a little bit more about money.

I think when a lot of people think about money and kids and middle school, they're not really

thinking about the stock market or a 529 plan.

They're thinking about allowances or how to do money right or better with kids.

Any opinions from my talented panel about things that aren't investing but are money

for middle school kids? Barnes: I'm just going to say a disclaimer.

I do not have children, but one of the things I remember as a child, in terms of allowance,

is I had a really good friend whose parents provided a monthly base allowance and then

they would get different dollar increments depending on the chore.

You would get your $10 a week, but if you decided that you wanted to mow the law or

shovel the snow off their long driveway and the stairs, then you got an extra $20.

If she babysat her younger siblings, she would get an extra $5.

So however that played out, it would teach the value of save, share, and spend.

Utilizing that where it's automatic, and every time I receive an allowance, a portion of it,

whether it's $1 or $2 is going towards saving, going towards spending, and then also

going towards sharing if you want to teach them to be philanthropic.

Gardner: When I think about allowances, I think of just how incredibly lame I was as a parent...

Brokamp: I'm with you! Gardner: … and how inconsistent... Robert? You, too?

Brokamp: Yes.

Gardner: We were so not best practice on allowances for kids.

We did it sometimes and not others.

There was no earned component, which I think Naima spoke very well to.

I still feel OK with how our kids have turned out, so I'm not sure it's all about having

the right way to do allowances, but I'll say this, Robert.

You can be pretty bad at it and not do, I hope, permanent damage to children.

Brokamp: I will say I'm pretty confident that the evidence is clear that whether a kid got

an allowance or not did not have a huge impact on whether they were financially successful later in life.

Because I looked that up. Chores are a different thing.

It is good for kids to do chores, but the allowance was not as important,

which made me feel good because I was horrible at doing it.

Mostly being the kids would say, "It's time for my allowance and I didn't have the cash."

That was the problem.

Gardner: We also weren't great at tooth fairy, for the record.

When it came to, "Mom! Dad! The fairy didn't come!" I'd say, "Oh wait!

No, no! No, honey, honey, honey! Look back underneath. Oh, it fell!

Over here on the floor underneath the pillow!" Brokamp: It fell in my pocket!

Moser: You're playing a game. Part of it is to try to find it!

Gardner: I also want to say something before we move to chapter three, our final chapter,

about matching, because while I never did this, we have had some great stories.

We've told them in some of our Motley Fool books of the past true stories about

usually kids with a lot of initiative who realized, just like we talked about, the power of corporate

matching like your company matching your 401(k) donation.

Let's say your child saves a dollar.

You could say, "For every dollar, honey, that you save, your mother and I will give you one extra dollar."

But some kids have an extra dose of initiative and so the stories that we've told through

our books are kids who said, "You know, beyond just Mom and Dad, I have aunts and uncles who love me.

I have grandparents who love me. I have mentors that might be proud of me if I got an A."

And so there are stories of kids who, for every dollar they save, all of a sudden twelve

additional dollars are being triggered through conversations with family members.

For every "A" that was earned.

And then you can have huge amounts of money sometimes -- well more than you would expect

-- if you have a culture surrounding you that wants you to succeed at saving or doing well in school.

So before we move on, I want to talk briefly about the power of matching.

You hope your company or workplace does it for you as a professional.

Darn it, you can do it. I would encourage us all to do that.

For younger people in our lives, if they do something well, give them an extra buck match.

Moser: I agree. I'll say that while we, in concept, have matched, we didn't really apply a formula or

any sort of consistent philosophy to it.

It was more I'm kind of lazy and I don't really

want to keep track of all the numbers. Gardner: Yes, the Brokamp/ Gardner approach

to allowance. It was kind of lame. Lazy, but well meaning.

Moser: Tooth fairy money or birthday money -- part of that would be you may have that

to spend, but part of that we want to put into your brokerage account so that you can

contribute to your investments and have some ownership, there.

And then my wife and I would help top that account off so they could buy a few shares

of a given company, so we really didn't apply the formula dollar for dollar, but the concept,

I think, still works.

Gardner: In the story that I was thinking of, Jason, it was as much the child.

She was just on fire when she had this matching and then started to realize in the most enterprising

way that she could get all kinds of people; maybe like the mailman.

Everyone's contributing matching what she was doing.

Some of these stories or ideas are going to make sense to some of us and not others.

We're just trying to paint as much of the canvas as we can, knowing, in the end, that

it's each person's individual, unique portrait.

Well, we've been promising chapter three, so let's now advance to chapter there.

Now we're at the age where you're getting somebody started investing.

You weren't ready for them when they were newborn and you may have had some of these conversations.

Maybe there was part of the Gardner/ Brokamp alliance of lame allowance approach.

But here you are finally and darn it, this person has just graduated high school.

They've got a diploma and a smile on their face. Or maybe college.

Or maybe just a little bit after that.

So we're talking about adults or near adults and getting them started investing, and certainly

that's true of many people hearing me today.

And a few months hence it's going to be graduation time all over again.

Yes, the winter will finally thaw and spring will spring anew, so let's talk about that

stage of life and getting "kids" started investing. Daniel?

Masseca: It's funny that you were talking about matching a moment ago, because if you're

the parent of a college-age student or a recent graduate, what I have actually seen the most

often is those are the people who you motivate through matching, because they don't have

money to invest themselves at that point, and they really don't want to siphon off funds

when they need it for anything else.

So I've seen a lot of parents trying to motivate them to put dollars in, by matching dollars

in those instances, when they might not have been brought up to save on their own.

Gardner: That makes a lot of sense.

So in addition to that first job that they're hoping to get after high school or college,

and have a matcher in their employer, we could do that as parents, or aunts and uncles,

or whoever we are.

Brokamp: And I do think it's important that if they are starting a job -- they've just

graduated from college -- you have that conversation about the 401(k).

You say, "Listen, that's one of the first things you should do."

Most plans do have a match. You want to sign up as soon as possible.

The thing I've told my kids, over and over again, is if you want to retire in your sixties

you've got to save 15% of your income as soon as you start working, and that includes the match.

So here at The Fool if you contribute 9%, The Fool matches 6%, and you hit that 15%.

I've drummed it into their heads that as soon as they start working, they've got to save 15%.

Barnes: And even if you are unable to save the entire 15% you may not want to discourage

[people who are in that situation] in the beginning.

It's being able to get the match and get 100% of the match.

If they match 100% up to 6%, you want to get that 6%, so make sure you put in 6% and then

you'll be able to get some free money.

Brokamp: Even to the point of helping them fill out the forms, because I think that's

one of the big stumbling points with a lot of financial planning stuff.

Whether it's applying for life insurance or opening a brokerage, they look at these forms

and they don't even know how to answer some of the questions

[the beneficiary designation and stuff like that].

Help them with the paperwork to get them over that hurdle.

Gardner: Yes, I was wondering about that, Robert, because we talked earlier in the show,

in chapter one, about those different types of accounts you can start, and we gave you

a few marching orders, I hope, to do that.

What is it like when you've got an adult on the other end, let's say a 22-year-old?

Can you fill it out for him or her or, darn it, should they be doing it at that age themselves?

If it's intimidating, how do we march people into an office and get them to sign a form to get it going?

Brokamp: Well, I've been helping my oldest daughter, who's in her twenties, open up a Roth IRA.

I would say you do it together. I told her where I think she should do it.

I told her, her investment options.

I'm not going to tell her how to invest, but these are the investment options. Center the link.

She's going to be at our house tomorrow night and we're going to seal the deal and

make sure she's taking care of it.

Gardner: And I'm sure you've written yourself in as the beneficiary designate.

Brokamp: Absolutely! Gardner: And that's why you're in this process.

Barnes: My sister recently got a new job and we had a conversation about everything from

picking her health insurance to deciding whether she's going to get life insurance through her employer.

Gardner: Will you come over to my house, Naima? It's not just her that would benefit from some of that.

Barnes: Yes, so definitely doing that.

And then talking to her about the importance of using her 401(k).

She's also planning a wedding, so being able to create that budget so that you can save

for the wedding since that's going to be something coming soon.

But also being able to help save for your retirement, even though it's many years away for her.

Gardner: Naima, earlier today in Fool HQ we had a Fool's School [one of our Fool's School sessions].

We had some 22ish-year-olds in there and we were speaking to them.

You were there, because you're one of our heads of Fool's School and Jason you've done

a lot for Fool's School, too.

I know that you're both experienced talking to people of different ages.

Naima, what are one or two things that you said to the young man who came and visited

us earlier today that would be applicable to anybody listening here?

Barnes: The biggest thing we talked about today is that anyone can be an investor.

A lot of times the message is that you have to be something who is older and knows a lot

about money in order to invest, but you can be someone who works in any type of position.

It doesn't have to be a position where you're making $1 million a year or some six-figure amount.

We also talked about the three things that they can potentially do today and getting

started as soon as possible is one of the biggest things outside of the three things.

We talked about the three accounts that they can open in order of importance with one being

the employer-sponsored plan if their employer offers that.

Gardner: So if they can only open one account, you would say that type of account first.

Barnes: That would be the one I would say first. Gardner: Because your employer is matching.

Barnes: Yes. Gardner: I heard you say free money.

Barnes: Free money. You want to get free money.

Who doesn't want free money?

Then second, if you're preparing for retirement; although it is very far away for people who

are in their twenties, it still should be something that you keep on your mind because

I know that I want my seventy-year-old self to be able to enjoy her life and also be able

to help her children and grandchildren when she does decide to have them.

So being able to use a Roth IRA or a traditional IRA to save for retirement after your plan from your employer.

And then for shorter-term goals I like to use just a taxable account or for things that

are going to be outside of the amount you can put in an IRA.

I like to use the taxable account for that, too.

Masseca: That was my first financial planning lesson -- when I was 19 years old and got

my first job in college -- was learning the power of the Roth IRA.

My uncle made me read a book [about] building your Roth IRA wealth, and it was really eye-opening

about the power of compounding with an account like that.

That's when I opened my first account and started putting some money of my own into

a Roth IRA and investing there.

Gardner: Obviously at Fool.com and other resources, too, you can read a lot more than we can cover

in a given podcast, but I think the headliner there, Daniel and everybody, is that the Roth

is often a great choice for younger people [the ones we're talking about, right now,

in chapter three], because you're paying a tax up front on the money that you put in.

This may sound like a bummer, because if you put in $1,000 you have to pay like $200 of it right up front.

You're only getting to invest $800. But here's the good news.

You let that money compound over a few decades and there's no tax you pay on the other end,

so the math works out wildly in our favor often if we go with the Roth IRA for young people.

Moser: And I think it's probably worth considering having a little bit of everything.

I loved your approach of a nice, taxable brokerage account where you'd have the ability to do

some stuff with that money as you're living your life.

I have the same and it helps when we want to travel or go do something.

Then I've got my retirement account, here, with The Fool and that's a Roth 401(k).

And then I have a conventional IRA that is just all of the different jobs I had before,

where I rolled over the retirement savings that I had accrued from those jobs.

So you have a little bit of it all and it does make a difference, because with those

conventional IRAs, once you start taking that money out and you eventually will have to,

you're going to be taxed on those withdrawals, whereas with that Roth, you're not going to be.

So it's nice to have a little bit of diversification there, which is, of course, what we preach

when it comes to stocks, as well.

Brokamp: And so many younger kids, especially if they're working in high school and college,

are not making enough money to even pay taxes.

They're making less than the standard deduction.

You wouldn't be paying taxes anyhow, so the Roth is a no-brainer in that situation.

Gardner: Well, I feel like we're getting near the end of our conversation.

This has been a lot of fun.

More importantly, though, I hope it's been really helpful for you, our listener,

whether you're listening to this in January of 2019, when it was originally taped to start the new year.

What better way to start a new year, if you're here around Fool HQ, then to have this conversation?

Or maybe you're hearing this months or years later.

I hope that this information and maybe beyond information -- perspective --

maybe a little bit of wisdom, here, from The Motley Fool is helpful for you.

Let's close this way, team. Let's go with our final bit of advice.

So reflecting back on the conversation we've had. Also if you think we've missed anything.

I don't want any listener to feel like, "They never talked about this or that."

Any final thought or suggestion. Let's start with Naima.

Barnes: I'm going to go with two. One is start today. Start today.

And then the second thing that I didn't mention earlier is a great platform called Stockpile

that is really cool for gifting.

A grandparent, parent, an uncle -- instead of giving a holiday gift -- why don't you give them stock?

You can buy gift cards from Stockpile from

denominations of $25 up to $2,000 and that's pretty cool.

Then they can go and invest, even in fractional shares through their website.

They also have ETFs.

Gardner: They're also not sponsoring this episode of Rule Breaker Investing, but Stockpile.com,

spelled as one would expect.

It's fun, because you can give a gift card, except rather than get $25 off at Starbucks

or Chipotle, you can actually get $25 toward ownership of Starbucks or Chipotle.

I think all of us around the table and I trust many of our listeners realize which is more valuable 10 years later.

Barnes: It's pretty cool. And they do also offer custodial accounts, as well.

Gardner: Well, that makes a lot of sense given their business model.

Thank you, Naima! A delight to spend time with you this podcast. Daniel?

Masseca: If I were to give advice for helping a kid get started investing, my two things

would be to keep it simple [they don't care about Roth IRAs or custodial accounts].

They don't need to know. Just do it. The other would be to make it fun and make it engaging.

Make it something that they can relate to.

That way you're building a passion instead of just something happening in the background.

Gardner: Robert?

Brokamp: I will piggyback on what Naima said and that is just to do it.

Our biggest mistake was to try to find the perfect solution and the perfect investment,

and we procrastinated too much.

We funded accounts, and I felt all this pressure that these are our kids' first investments

and I want to make sure we get it right. In the meantime that money just sat in cash for too long.

So don't worry if it's not perfect.

Whatever investment you pick will teach a good lesson.

Moser: Those are really hard to top, so I'm going to try to expand a little bit.

Gardner: That's legit. I'm doing the same thing.

Moser: I'm going to actually show we do have a video component I think, right?

Gardner: Yes! Moser: For those watching on YouTube.

Gardner: Yes, we're on YouTube!

Moser: When we're talking about gifts, holiday seasons, birthdays, they're a great time.

I love stocks as a gift idea. You don't have to pick them up off the floor.

They don't require batteries. They're not going to break.

And it's as easy as just transferring from your account over to their account, too.

Gardner: Love it! Moser: And you print out a nice certificate.

See, that's what I'm giving my daughters.

Their mom and dad are giving them five shares of Square, each.

And they know Square because they see it everywhere we go.

They realize, "Oh, you're paying with Square." They see the Square stuff, there.

I think giving stocks as gifts is just an awesome idea. I love it.

And you don't have to worry about that matching thing, David.

You're just giving them all that money right up front.

Then to Daniel's point, keep it fun.

I mean, going back to the very lesson that introduced my daughters to it

[and I've told this a million times, but it never gets old]. It was just us going to lunch at a Panera one day.

They were five and six years old, and I told them that we happened to own a little piece

of that restaurant. They couldn't believe what I was telling them.

And, of course, it was just through Panera shares ownership, but that's what got that

discussion started and it kept it fun.

So from there they see their portfolio, and they see that as these are all the businesses

that they're owners of, and these are the businesses that play into their lives in some way,

shape, or form. That keeps it fun and that keeps it interesting.

Gardner: Often people say last but not least, but I'm going to go with least,

because I like what you all said.

So last and least, I'm going to say that a lot of what we've talked about is about touching off

and getting somebody started. Switching that person on.

But after that, the rest of the game is about staying "in the game."

So if we've made any mistake with this podcast, we gave you some scaffolding.

We gave you a guide and a little bit of inspiration to get somebody started.

But really, it's about staying in the game. It's about saving.

That's the hardest thing to do in our world today.

The reason most of the world isn't an investor today isn't because they trade in and out of the market.

Some people do make that mistake, but really, much of the world isn't in investing

because they don't have capital yet, and that's because they haven't learned to save.

And we've seen people in desperately poor circumstances be net savers and it's always

very inspirational to me and to us here at The Motley Fool.

So I believe anybody can do it. You can do it.

You can do it on behalf of a younger person, as we're talking about here.

But it's about saving and then it's about adding and making a lifetime commitment to

your financial future or, in this case, that of somebody else's.

Making it clear to them that even if it's a bear market, and even if 2018 didn't end well

for the stock market, who knows about the future?

Whenever you're hearing this, who knows what it holds, except that I think it's going to

be better and especially if you give it time.

For Naima Barnes, for Daniel Masseca, for Robert Brokamp, and Jason Moser.

I'm David Gardner wishing you the very best at touching off positivity in somebody else's life.

Somebody younger than you -- maybe more than one person --

and getting him or her started investing. Fool on!

As always, people on this program may have interest in the stocks they talk about,

and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks

based solely on what you hear.

Learn more about Rule Breaker Investing at RBI.Fool.com.

For more infomation >> Great Life Advice for Kids: Start Investing Young - Duration: 54:28.

-------------------------------------------

AbsorbPointer (Flutter Widget of the Week) - Duration: 0:59.

♪ (intro music) ♪

Most widgets offer some way to disable input.

If you set the onPressed callback of a RaisedButton to null, for example,

it becomes disabled.

And you can use NeverScrollableScrollPhysics

to tell a ListView not to scroll when the user drags it.

But if you have a complicated subtree of widgets

and just need a simple way to wall them off from touch events,

try AbsorbPointer!

Just put it at the topmost point in the widget subtree you'd like to block,

and even though you can't see it,

it'll keep touch events from getting to all the widgets below.

You can use the absorbing property

to quickly turn the AbsorbPointer on and off,

and the ignoringSemantics property

lets you control whether screen readers and other features

will ignore the blocked widgets.

For more info on AbsorbPointer and all the other Flutter widgets,

head to flutter.io

♪ (music) ♪

For more infomation >> AbsorbPointer (Flutter Widget of the Week) - Duration: 0:59.

-------------------------------------------

There are Beings on Earth who are Smarter than Humans - Duration: 2:42.

It has long been known that we, humans, are the smartest beings on Earth.

However, shockingly, but it seems there is a smarter species than humans, people!

What species is this?

Hey there, This is Bhaskar Banerjee and you are watching YouTube Channel Bhaskban.

A study in 2018 suggests that dolphins are very intelligent creatures, so much that they

can overcome human intelligence in some respects.

One of these features is self-consciousness.

The study used was a mirror self-recognition test, which essentially consists of presenting

a mirror to the subject being tested and seeing how long it takes to recognize it.

When placed in front of a mirror, human children can usually only be recognized after the age

of 12 months.

Dolphins, on the other hand, can only be recognized in just seven months.

The experiment was done on dolphins, both males and females.

But more than that.

Dolphins are capable of more than you ever imagined.

They are even able to create personalized sounds, which are the equivalent of their

names.

They can solve different problems and communicate with each other without any difficulty.

Some think we should treat them as people from a certain point of view because of their

superior intellect.

For more infomation >> There are Beings on Earth who are Smarter than Humans - Duration: 2:42.

-------------------------------------------

Ostrich Line Drawing for Kids - YoKidz - Duration: 1:24.

Ostrich Line Drawing for Kids - YoKidz

For more infomation >> Ostrich Line Drawing for Kids - YoKidz - Duration: 1:24.

-------------------------------------------

SONGOKU VS FRIEZA, CELL AND MAJIN BUU - EPIC BATTLE SUPERHEROES COMIC - Duration: 15:55.

SONGOKU VS FRIEZA, CELL AND MAJIN BUU !!!

For more infomation >> SONGOKU VS FRIEZA, CELL AND MAJIN BUU - EPIC BATTLE SUPERHEROES COMIC - Duration: 15:55.

-------------------------------------------

3 Biggest Healthcare Stories At #JPM19 This Year - Duration: 31:45.

Shannon Jones: Welcome to Industry Focus, the show that dives into a different sector

of the stock market every day. Today is Wednesday, January 9th. I'm your host, Shannon Jones,

and I'm joined via Skype by all-around good guy, Todd Campbell. Todd, how are you?

Todd Campbell: I'm great, Shannon! How are you doing today?

Jones: I'm doing well! I must say, I was so excited to record this show with you today

because there's been so much news coming out of the biopharmaceutical space, which we'll

get into. Todd, what a way to start 2019! Campbell: There's going to be a lot of people

listening to our show today who are going to be thinking the same thing: what do I do now?

Of course, we'll get into that in a second. Yeah, there was a quite a splash at the

JP Morgan Healthcare Conference beginning this weekend.

Jones: Yes. For listeners who maybe are new to the healthcare space, the JP Morgan Healthcare

Conference is the Super Bowl of healthcare conferences. It's where literally thousands,

maybe 30,000, scientists, business development people, investors descend on San Francisco.

That almost sounded like a plague. Probably not too far from the truth.

Campbell: For residents, maybe it feels that way.

Jones: Probably so! You've got hotel prices going up, I've seen as high as $20,000 for

four nights in San Francisco. But, for new listeners, you get the idea -- this conference

is about companies presenting the latest on their pipelines, giving updates, and more importantly,

making some very strategic deals. Let's start the show with the deal of deals,

the one everybody's been talking about, Todd, and that would be the mega-merger of

Bristol Myers Squibb and Celgene. To catch our listeners up, this was a deal that was announced on Thursday.

You typically see that heading into the JP Morgan Conference. You'll see the bigger

M&A deals announced sometimes right before the conference starts on Monday, sometimes

on that first Monday. This year did not disappoint. A huge deal, Todd. A $74 billion deal. Actually,

$95 billion if you factor in the debt. I have to say, I did not see this one coming.

Campbell: I was expecting Celgene to be on the other side of that trade.

Jones: You and me both! Campbell: Yeah! I was expecting them to

come out and say, "We're going to buy _____, this collaboration partner we've been working with!"

Last year, we had that ImpactBio acquisition that they announced. Then, a couple of weeks later,

they announced the Juno Therapeutics deal. There's been a lot of talk and chatter

that Celgene, to fuel further growth in the future, maybe it would go out and do some

additional acquisitions. But lo and behold, it was not the acquirer! It was Bristol Myers

Squibb that was the acquirer of it.  It's a huge deal. You mentioned, not including the debt,

a $74 billion deal. There's a lot of moving pieces to this deal, though.

I'm sure that a lot of our listeners are looking at this deal going, "Is that it?"

Jones: Let's break that down even further. There are a couple of different components

to the deal. Right now, what's going to happen is, Bristol will acquire Celgene. For every Celgene,

you'll basically get one share of Bristol. You'll also get $50 in cash.

And then, they've got this really interesting contingent value. It's $9, it's a tradable

asset that's contingent upon approval of three products actually reaching the finish line.

So, multiple components to this deal that ultimately had Celgene valued at about $102 a share.

Honestly, Todd, I think for a lot of Celgene holders, that was not the price

that they were expecting. Campbell: No. Me included. I'm looking at

this deal and saying, "Wait a minute... " Bristol Myers sold off on the news. That's common,

for the acquirer to sell off on the news. When you take the $50 in cash, plus the Bristol Myers share,

we'll ignore the $9 contingent value right, the CVR, for right now because

it's not guaranteed. We may or may not get that in the future. And you're talking about

a sub-$100 price, for a company that, in 2017, was trading around $140. Shares traded above

$100 for most of the period from 2014 to 2017. So, yeah, I think a lot of people are probably

scratching their heads, going, "Geez." A lot of investors may even be sitting on a loss,

even after this acquisition was announced.  Jones: Yeah, naturally. It's worth noting

here that both companies have floundered. That $140 share price has certainly come down.

Celgene has had a couple of missteps along the way. Todd, you and I have talked about

this in some of the previous shows. Campbell: Just a few! [laughs]

Jones: [laughs] Just a few. Bristol has certainly taken a beating, has fallen behind rival Merck

in the checkpoint inhibitor race. These are two companies that have really been trying

to find their footing, now coming together to form this mega-conglomerate. For those

healthcare investors out there that may not be aware, oftentimes these big biopharma mergers

don't end up so well. So, there's a lot of uncertainty here.

Speaking of uncertainty, Todd, we've gotten quite a few questions. One that really sums

up a lot of the uncertainty, a lot of the head scratching, came in from Tom on Twitter.

Tom, thanks so much for writing into The Fool. He says, "What questions should Celgene owners

be asking themselves in deciding to sell or hold? It seems time for a new thesis or a reallocation."

Well, Tom, this is a great question, we're so glad you asked.

Todd, what do you say to that question? Campbell: I think the first question I ask myself is,

is this deal enough? Celgene is saying that their 2020 earnings per share

will still be $12.50. If you take a look at Bristol Myer's current price, Celgene $50, that's

7.8X forward earnings that Bristol Myers is paying to land Celgene. And Celgene

is a much faster growing company. It's growing its top and bottom line by double digits,

while Bristol Myers is growing 7-8%. So, that's question No. 1. Is this enough.

And, will any shareholders therefore balk? And could that mean that some other company swoops

in and says, "I'll make a competing offer for you, Celgene?" Or, maybe they go out and say,

"I'm going to buy Bristol Myers now, and I'm going to get Bristol Myers and Celgene altogether."

That's been floated, as well, although the likelihood of that's pretty small

because there aren't that many companies that could swallow a deal that big.

Jones: Exactly. You've also got the financing in play. It looks like this deal right now

is set to close in the third quarter of this year, but there certainly is the chance that

someone could swoop in and maybe sweeten the deal for Celgene shareholders. Like you said,

I don't see that likely. General consensus is, Bristol got an awesome deal for Celgene,

but Celgene shareholders are still left holding the bag.

Todd, you actually did an amazing series on what this means for Celgene shareholders,

and also what it means for Bristol shareholders. I encourage our listeners to check out those

articles on fool.com. Another good question is deciding what kind of investor you are.

Campbell: Right. Am I a growth investor or an income investor? You want to know whether or not

you're going to buy, sell, or hold this stock. Actually, we got a question to that.

The question being, "What do I do now?" I think you really have to figure out,

do you want your portfolio to be focused on double-digit growers who are plowing all of their money

back into research and development to fuel future growth? Or, are you more interested

in owning a slower growing company that, obviously, still reinvests some money

into research and development, but also pays a dividend? That's one of the big differences

between Bristol Myers and Celgene. Bristol Myers pays a relatively healthy dividend.

But you're not going to get the same needle-moving reaction from winning the approval of one drug

in a combined Bristol Myers Squibb-Celgene as you would with Celgene as a standalone.

It just won't happen. Bristol Myers Squibb plus Celgene, however we want to do that mash-up name.

They're going to do about $40 billion in annualized sales based on last quarter.

You need to generate $4 billion, drugs that create $4 billion in sales,

just to move the needle by 10%. Jones: Yeah. Combined, you're looking at a

pretty impressive portfolio, though. This merger could potentially set up this company

to have the second leading oncology portfolio behind Roche, which is quite incredible.

It takes a lot of the pressure off, for example, concerns about Revlimid. That's been Celgene's

bread and butter, makes up over two-thirds of revenue for the company. There have been

a lot of concerns about upcoming generics starting to erode sales for that drug.

This certainly takes the pressure off. Now, you have I believe six potential new drugs coming

on the market within the next five to seven years, potentially another $15 billion in

revenue that could be unlocked with that. It certainly makes it intriguing moving forward,

but yeah, I think it comes down to, will you be satisfied with not having the high growth

rates that you saw with Celgene as a standalone? Campbell: Yeah. If you're a growth investor,

you're probably going to want to focus on other ideas. But if you're a growth/ income investor,

someone who will play in both, like me -- I do that, and I own Celgene,

and I plan to continue to hold Bristol Myers after this deal is done. I run a pretty diversified portfolio,

and I'm fine with having a company like Bristol Myers in there. You make a great

point about the oncology franchise of the combined company. If you look at the combined company,

you're going to have Opdivo, Sprycel, Yervoy. You're going to have Revlimid, Pomalyst, and Abraxane.

Combined, those drugs generate about $6 billion in sales per quarter.

We've talked about the attractiveness of oncology in the past. It's an important market.

Demand for those drugs is inelastic. If you have cancer and you need treatment,

you're going to get treatment. You're not going to put it off because of economic concerns, necessarily.

That makes them a big player in oncology. Also, they get Otezla. Otezla is great for

Bristol Myers because they have another drug in autoimmune disease called Orencia.

Orencia is losing its patent protection. Now, it's a biologic. There are no biosimilars that

are about to launch for it. But eventually, you could have biosimilars start to eat away

at Orencia's sales. Adding Otezla in to Bristol Myers' product portfolio offsets some of that

potential risk for the company down the road. So, yeah, you have drugs that can move the needle.

You've got that CVR that we talked about before. That applies to the approval

of liso-cel, which is the lead drug that Celgene acquired from the Juno Therapeutics.

That's a non-Hodgkin's lymphoma drug. That has to win approval by the end of 2020.

You have to get approval for Ozanimod, which is the multiple sclerosis drug that's had some stumbles

that has to win approval before the end of 2020. Then, you've got bluebird bio's bb2121.

Celgene is collaborating with them on that drug. That has to win FDA approval by March 31st, 2021.

If they don't win approval, then you don't get the extra $9.

That's something that you have to be thinking about, as well.

Jones: Let's dive into our second question

that came in from Ahmet. He says, "Under the terms of the deal, Celgene shareholders will

receive one Bristol Myers Squibb share and $50 in cash for each share held. Since the

current price is around $81," this was at the time that he wrote, "for Celgene and Bristol is $45,

does it not make sense to buy Celgene now and get $45 in stock plus $50 in cash,

which equals about $95, a profit of about $14 per share? Am I missing something here?"

Campbell: Kind of. You have to remember, there's always risk associated with a deal after it's

been announced to when it closes. In this case, you've got two risks you have to consider.

You have to consider not only what could go wrong at Celgene between now and then,

but also what could go wrong with Bristol Myers Squibb between now and then. A stumble at

either one of those companies could somehow negatively impact that deal. If Bristol Myers

shares sell off, the value of this deal falls. So, you build in some protection.

That's why you get that arbitrage opportunity where you have the difference between, as the listener

pointed out, the value of the $50 plus the BMY shares, while Celgene is trading today

below that amount. Overall, I like it. I would say, yeah,

go ahead and do it. I feel pretty good about the odds of this deal closing or something

better happening between now and then. But there is risk. That risk would be if something

goes wrong with one of the drugs that Celgene's researching, one of the drugs that Bristol Myers

is researching, who knows. Jones: Fair enough. I have to agree there.

It sounds like an awesome opportunity. I, of course, am looking more long-term at what

this deal means. One of the things that came up in the conference call was the potential synergies --

yes, I used that word, Todd. There were synergies of potentially $2.5 billion.

What that comes down to is cost-cutting and layoffs. Ultimately, what it comes down to is,

they're going to start to shelve some potentially promising candidates down the line.

When you've got resources combined, yes, you do have some duplication of functions

and resources. But, they're going to have to make a decision about which products they

want to move forward with. You can't win them all. It'll be really interesting.

There's a lot of risk long-term in what that looks like for these companies.

Generally speaking, when you see large biopharma, and large pharma in general, they do tend

to be a little slower when it comes to innovation, and a little more unwieldy when it comes to M&A.

I mean, here you had Bristol and Celgene, two of the most dynamic M&A players in the space,

now joining forces. It'll be sad to me to not see a new press release about Celgene

buying up a new company, Todd. But, it'll be interesting to watch moving forward.

A lot of question marks, a lot of uncertainty. For most investors right now, I think, let's hold

the line and see. Would you agree with that, Todd?

Campbell: I think so. Like I said, I own Celgene. My plan at this point is to ride it out,

take my $50 and my Bristol Myers share and hope for the best on the CVR, and hope that Bristol Myers

can execute on its plans. You mentioned the synergies. They're saying this is going

to be immediately accretive to a pretty good tune. The upside is that both of these companies

are very profitable companies. It's not like integrating them together is going to create

a very large drag. Bristol Myers as combined company should see its operating metrics improve

following this deal. Keep an eye on that.  Jones: Yep, keep an eye on that. No surprises

that the next story on our list is also a big M&A deal coming out of the JPMorgan Healthcare

Conference this week, and that is none other than Eli Lilly, ticker LLY, announcing that

it will be purchasing the genetics oncology player Loxo Oncology, ticker LOXO.

It's a deal worth $8 billion in cash, and one that really adds to the string of deals Eli Lilly

has been doing to try to beef up its oncology portfolio. Todd, we've now got two big M&A

deals focused on the oncology assets. Campbell: Yep. Eli Lilly is probably best

known for being a leader in diabetes. It makes Humalog and a bunch of other important diabetes drugs.

It's also long been playing in oncology. Its stated goal is to boost the amount of

sales that it gets from those indications. This deal certainly puts it on the cutting edge

of what we'll call the next generation, perhaps, in how doctors treat patients who

have cancer. Loxo Oncology actually has won FDA approval for a really unique drug

that works unlike most of the other cancer drugs that are out there on the market.

Jones: One thing I'll mention is that this deal actually represents a 66% premium to

Loxo's closing price of $139 a share on Friday of last week. Unsurprisingly, we saw the shares

of this company skyrocket nearly 66% on the day that it was announced. It all comes down

to this new innovative approach. It's targeted and focused in on precision medicine.

You mentioned that they've got a drug out called Vitrakvi. It focuses on fusion genes. It's these genes that,

when they fuse together, flip a switch. And then, all of a sudden, now you have these

cancer cells proliferating. Loxo Oncology has come on the market with drugs that could

potentially be game-changers in this space moving forward.

Campbell: We've talked on the show in the past about what's happening in cancer treatment.

We're moving increasingly away from treating based on the origin of the cancer -- so, breast cancer,

prostate cancer, ovarian cancer, whatever -- and more to the biology or the genetic

mutation that may be contributing to the disease.  What Loxo's Vitrakvi -- that's not an easy

one to say, is it! -- what that drug does is, it can be used in various solid tumor cancers.

It doesn't matter where it originated. According to the companies, it's not a ton

of patients that have these TRK fusion mutations, but it could still be thousands of patients

that are eligible for treatment. Lilly is going to have to split, in the U.S.,

any sales from this drug with Bayer. Bayer licensed 50% of the rights to any profit on the drug

either one or two years ago. Prior to the approval, anyways. Outside the U.S., what'll

happen is, Bayer will market it and pay Lilly a double-digit royalty on sales.

But that's not the only drug that Eli Lilly gets in this deal. It also gets LOXO-292,

which potentially could be in the leadership. It could get to the market before some of

the other competitors that are also working on drugs that work similarly. It inhibits

something called RET. RET fusions are estimated to be present in about 2-3% of non-small lung

cancer patients, and, it varies depending on the type of thyroid cancer you're looking at,

but still, again, thousands of patients potentially for an addressable market for

this drug. In trials, the results for LOXO-292 have been pretty good. That's got some people

thinking that that could be a major drug, as well, and Lilly will own 100% of the rights

to 292. 292 has not been licensed out to anyone else, at least not yet.

Jones: LOXO-292 is potentially the more lucrative option here for Loxo and Eli Lilly, so certainly

keep your eyes on that. But, I'm glad to see Eli Lilly becoming much more aggressive in

building out their oncology portfolio. They were pretty late to the game when it came

to cancer immunotherapy. You saw Bristol and Merck getting out the gate with their checkpoint inhibitors.

Now, Eli Lilly has had to play catch-up. To see this deal -- they also had

a deal in May of 2018 for ARMO BioSciences targeting the patients who weren't responding

to checkpoint inhibitors. So, you've now got, potentially, an oncology portfolio that is

not being addressed by a whole lot. Granted, they are very small patient populations.

But, it's very intriguing to see Eli start to become much more strategic and aggressive in their approach.

Campbell: Yep. There are two other drugs, too,

that are worth knowing about that they're going to get in this deal, LOXO-305 and LOXO-195.

LOXO-305 is designed to overcome resistance that can build up in patients taking the mega-blockbuster

Imbruvica. LOXO-195 is a second-generation TRK fusion drug. If we discover that people

are starting to develop resistance to TRK fusion medicines like Vitrakvi, then this

drug could theoretically get used, as well.  So, yeah, there are some exciting things going

on here. Like you said, interesting to see both of these really big -- Bristol Myers

and Eli Lilly -- big, traditional pharmaceutical companies making big splashes that advance

them into next-generation biologics.  Jones: Turning the page a little bit,

let's talk about a smaller player in the space that also made headlines this week. That would

be the clinical stage biotech SAGE Therapeutics Inc, ticker SAGE. Shares skyrocketed nearly

43% on positive data coming out Monday related to their postpartum depression drug, SAGE-217.

Todd, as you know, we love to see good data, especially in an indication like depression,

which, historically, you see a lot of these studies get overtaken by the placebo effect.

This is one company that I think has figured out multiple times how to make these clinical

trials run well and also have some impressive data results.

Campbell: Yeah, central nervous system disorders are extremely difficult to develop new drugs for.

There's been an absence of big advances for these disorders for many years now.

I was actually surprised when I looked at that market cap for this company. It's a clinical

stage company. They don't have any FDA approvals yet. They have one potentially on deck.

We'll get to that in a minute. But it already has a $6 billion market cap. It may be one of

the bigger biotech companies that many listeners may not be familiar with. They did, indeed,

announce results for SAGE-217's Phase III trial in postpartum depression this week.

That sent shares up 43% at one point on Monday. They're now up 35% over the past five trading days.

This is an important drug. You can't deny this.

Postpartum depression is underdiagnosed. There's a stigma associated with it.

Yet, there are still 400,000 cases of it, even though it's under diagnosed. And there really

aren't any treatments that are specific to postpartum depression. I mean, you can treat

them using other things that are used in depression and central nervous system disorders.

But, this theoretically could become one of the first -- I'll say "one of the" because we're

going to get to another drug in a second that SAGE is working on -- that targets postpartum

depression outright. Jones: One of the other things with SAGE is,

it's actually an oral drug. We've been talking around it, but what looks like to be a very

likely approval coming in March is their drug Zulresso. Zulresso is the IV infusion, I believe it's a 60-hour

infusion for postpartum depression that did get a positive nod from the Advisory Committee

at the FDA. I believe it was 17-to-one vote recommendation in favor of approval for this

particular drug. We could see that drug hit the market.

But now, you've got SAGE-217 right on its heels. It works very much the same, but has

a much more convenient route of administration, which could send the sales of the drug even

higher than the first drug that they have set to come out market in March.

Campbell: Yeah. This whole Zulresso story is interesting. The FDA originally had planned

to issue a go/ no-go decision on December 19th. However, in November, they pushed that

decision back. So now, an FDA decision isn't coming until March of 2019, which, of course,

leads investors to say, "Well, why did they do that? Are they uncertain of something they

saw following that AdCom vote? What caused them to want to delay their decision?"

It really just stems from the fact that the AdCom was based on the ability for there to be a

risk management system put in place for patients who do receive this drug, because it's going

to be a controlled substance. That plan was submitted to the FDA. Once you make a major

change like that, like submitting this plan, the FDA oftentimes will invoke its right to

delay by three months its decision. So, yes, the decision has now been moved to March 19th.

I think there's a very good chance that this thing wins approval. You hit the nail on the head, though,

when you said that it's not going to be a convenient treatment option.

It's going to be and inpatient option. Like you said, it's given intravenously.

So, this is not an ideal solution for this patient population, especially since it's a stigmatized indication.

A lot of patients that may be feeling the effects of postpartum depression

don't actually go out and tell their doctor about it anyway.

So, yes, we could get the approval of that. If we assume it happens, that'll be in March.

Then, the Drug Enforcement Agency has a 90-day window to be able to schedule the drug, because, again,

it will be a controlled substance. Once they get that in place, then they say

they're good to go. So, if it's going to get approval, this company is most likely not

going to see any sales coming in for this drug until the back half of this year, starting in, say, Q3.

Interestingly enough, that should also be

when we get more insight into SAGE-217 and its potential not only to be used in postpartum depression,

but also to be used in major depressive disorder. That's even a bigger treatment market.

That could be tens of millions of addressable patients, if it gets approved eventually, for depression.

Jones: Absolutely. The market is wide open

for SAGE and their depression drugs. A lot to watch here. I will say, with this particular company,

in 2018, this is one of those companies that was the talk of the town when it came

to M&A targets. I would not be surprised, especially coming off this positive Phase III

data for SAGE-217, to also see that heat back up in 2019, as well. A lot to look forward to,

certainly a lot on the docket. But, it's encouraging to see some good positive study

results coming out of JPM. Campbell: The other thing investors should

know is, they have a lot of cash. They've got a billion dollars on the books coming

out in September. They did file a mixed-shelf offering, but it was for an undisclosed sum.

They can tap investors for more money if they need it for their research. I don't know how

much more they'll actually need if they start bringing in some sales before the end of this year.

Then, as far as trying to think about,

it's already worth $6 billion, what could it be worth in an indication? You have to do some

guessing there. If you assume that they've got a billion-dollar blockbuster on their hands,

well, they're already trading at 6X that billion dollars at 6X sales. I usually think

that deals should happen somewhere between 3X-7X projected sales. You want to factor

that in as you're doing the calculus in your brain of whether or not you want to be buying

this stock on the potential for M&A. Otherwise, stay tuned. This company is going to have

a lot of data points coming out in 2019 that could move the stock up or down.

Jones: Keep an eye on all of that. More importantly, if you want to keep an eye on all the news

coming out of the JP Morgan Healthcare Conference, Todd and a whole host of other of our Foolish

writers have been writing feverishly away over these past few days. If you want to check

out all of their coverage in one place, we have put up a JP Morgan Healthcare Conference

round up on our site. If you just google

"The Motley Fool JP Morgan Healthcare Conference round up,"

you will find it. Be sure to check that out.

That's it for this week's Industry Focus show. Thank you so much for tuning in! Of course,

as always, people on the program may have interest in the stocks they talk about,

and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks

based solely on what you hear. This show is produced by Austin Morgan. For Todd Campbell,

I'm Shannon Jones. Thanks for listening and Fool on!

For more infomation >> 3 Biggest Healthcare Stories At #JPM19 This Year - Duration: 31:45.

-------------------------------------------

Falsa Identidad | Recap (01/11/2019) | Telemundo - Duration: 15:12.

We're even. Now get going.

My meth.

I paid you.

Whoa, whoa, whoa. Easy.

Give me my pills.

They're mine.

They're mine.

Don't be stupid.

Did you really think I'd give them to you?

As ------- ugly and skinny you are,

what you did was barely enough to pay for what you owed me.

You're pathetic, you whore.

Give them to me! Open the door!

Open the door, ------------!

I need them! Open the door!

Open up, -------!

I need them!

I need them.

Erick... come get me.

9th Street, number 75.

hÑ Don't do it.

Forgive me.

No, the time for forgiveness has passed.

Now comes the good stuff.

Now comes your farewell.

I'm doing this because of how much you disappointed me.

Die with some honor, you bastard.

No!

And to dust shall you return, Babel.

Fire cleanses everything.

What burns is erased forever.

I know you can no longer hear me, but I forgive you now.

For dust you are.

<i> Tell me something.</i>

<i> You think it's worth</i> <i> you staying</i>

<i> after everything</i> <i> they did to you?</i>

Wouldn't it be better to die

so they can no longer take advantage of you?

So they can't turn you into what you aren't?

Die!

Die, my love.

FAKE IDENTITY

The Gaona Cartel will never die!

Shoot at them!

So we're doin<i> Hey.</i>s tomorrow?

Did you get my present? Do you know who it is?

<i> I got carried away</i>

and left him on the fire for too long.

He burned.

It's Joselito, your adoring lover.

Why did you do it, Gavino?

Because that ------- was your lapdog.

He didn't think twice about betraying me to win you over.

Learn from what happened to him.

Sooner or later, everyone will end up like him.

Joselito was the first in a list of many.

Your name is on the list too.

and we'd go to the stables

and I'd make you ---- yourself laughing?

Isn't that love?

<i>If that bastard hadn't taken up</i> <i> residence in your heart,</i>

you and me might be married, with kids,

living a normal life.

Doesn't that sound nice?

We wouldn't have all this bloodshed.

All these deaths.

As hard as it is to admit, you might be right.

Maybe you're the only one who truly loves me.

I'm sorry.

It's my fault.

What if...?

What if you were the one?

You will always be my first love.

FAKE IDENTITY

where that couple lived.

Who knows if they're still there?

The important thing is that those documents were signed

with the name Emiliano Guevara,

but they weren't drawn up until after he'd died.

I found out in Alamos that the mayor

helped his brother, Diego, get out of there

by signing a death certificate.

But we now know that he is alive.

It was the mayor of Alamos who bought that house.

If you give me the address to that house

I can guarantee your peace of mind.

Hello?

Hello.

<i> What's up?</i>

Did you talk to the Colombians?

Sure did. We're all set.

We leave first thing tomorrow.

Where are you?

At home. I'm going to bed.

I'm ------- tired.

You should do the same.

We've got a hectic day tomorrow.

<i> We'll see each other then.</i>

Okay, whatever you say.

Okay.

Hey.

<i> Huh?</i>

After tomorrow, it's smooth sailing for you and me.

<i> Nothing but fun for us.</i>

<i>Everything's falling into place.</i>

That's right, darling.

Alright, get some rest.

Same to you.

Dream of me...

<i> but nothing too freaky.</i>

Get some rest.

Bye.

He said he was home.

What do we do?

Follow him, but don't let him notice.

I'll kill them!

Relax, Circe!

Let's go!

Did you think I couldn't shoot because I'm missing an eye?

Stupid old hag.

You killed my bro.

The boss wants you alive, but he didn't say anything

about not giving you a beating.

The truth is, I don't know that I want Felipa brought to me.o.

They're going to kill me.

Help me.

If you still feel any affection for me, please help me.

You said I could go on that mission with you.

You okay?

-Hey, are you okay? -I shot him.

I don't know if there are any more of them.

I don't know.

Did they hurt you?

No.

Thank you for coming.

I knew you wouldn't let me down.

Let's get out of here

before more of Gavino's people show up.

I came because I owe you a lot,

but nothing's changed between you and me.

Let's go.

Let's go!

Please help me.

Jesus! Oh, my God.

Yes, I'm coming!

What the...?

Oh, my God. What is this?

This is the same woman!

Maximiliano Guevara.

"Isabel Fernandez and Diego Hidalgo are accomplices."

-I told you. -Are you going to jail?

We have to go.

-Come on! -Pack a bag!

Police! Open up!

We're looking for Isabel Fernandez!

We know you're in there! Open the door!

Did you call Isabel just to worry her?

He's our contact.

We come in peace.

Put your guns away 'cause Santa Claus is here.

It's a thing of beauty!

This is my merch.

You outdid yourself, Romeito.

I don't know what's going on.

Circe is innocent! It was this ------- bastard!

What's going on? Me?

So you're the one who snitched to the DEA?

Relax, guys.

I'm just following orders.

Didn't you say you wanted to make history?

There you go.

Tomorrow you'll be in all the papers and on every newscast.

Congrats!

Not just us. You too, ------------!

------------!

Don't let him get away!

On your knees!

Freeze!

Drop the gun!

Drop it!

I won't miss the next shot.

Let's talk.

You son of a bitch!

but the other way around.

What are you going to do?

Are you going to forgive me?

Nope.

You're not that lucky.

Don't forget I was the one who saved your life,

like an idiot.

And you expect me to do the same

after all the ---- you've done to me?

----?

Pull the trigger.

Kill me.

If you don't, I promise I'll kill you.

I'll make sure of it.

Let's go! Hurry!

That way! Let's go!

Bitch!

Diego Hidalgo, put your han

For more infomation >> Falsa Identidad | Recap (01/11/2019) | Telemundo - Duration: 15:12.

-------------------------------------------

Trump responde ante nueva caravana | Noticias Telemundo - Duration: 1:00.

For more infomation >> Trump responde ante nueva caravana | Noticias Telemundo - Duration: 1:00.

-------------------------------------------

Divorcios y acuerdos prenupciales de los ricos y famosos | Un Nuevo Día | Telemundo - Duration: 2:49.

For more infomation >> Divorcios y acuerdos prenupciales de los ricos y famosos | Un Nuevo Día | Telemundo - Duration: 2:49.

-------------------------------------------

2 Hot Stocks to Buy for 2019 - Duration: 3:48.

Chris Hill: Aside from financials, in terms of individual stocks, what do you have your eyes on in 2019?

Andy Cross: Thanks, Chris, for that.

One that I think is set up to do well on a much larger size is Alphabet, the Google parent business.

When you think about all that they are in, and where they're taking that business.

Obviously, search and online advertising continues to be the huge driver, but they're involved

in so many other investments they're making. It's a $750 billion business.

They have about $100 billion in cash. They're making all kinds of investments.

Their YouTube business continues to grow.

I think it's probably more profitable than what we're seeing.

Online advertising will continue to evolve and grow.

Obviously, a company that size has some struggles when it comes to regulatory concerns.

The online advertising market, while it's evolving, is under some pressure, as we saw

with the likes of Facebook, when it comes to privacy issues and what that might mean

for the online advertising business.

But I just like what's going on at Alphabet, with the way that they've structured that

business with Google and the other businesses and investments they're making in other businesses.

And, the stock is really not that expensive. It's one that I like now.

On the financials side, piggybacking back there, a non-bank that I like is MarketAxess,

which operates the largest online bond trading platform. Hill: Wow, that sounds sexy! [laughs] Sorry!

Cross: They're basically trying to democratize and open up bond trading much like you've

seen with platforms and discount brokerages on the stock side.

It's much more complex, much more done old school through phones or text messages or

e-mails when you're trying to match up buyers and sellers of corporate bonds,

sovereign bonds, and lots of other fixed instrument investments.

They're the market leader.

They have the largest market share when it comes to online bond trading.

That's a growing market.

They're led by their founder and CEO, who's the largest individual share owner, Richard McVey.

It's extremely profitable. Returns on capital are exceptional. They're growing.

I expect that market to continue to evolve and improve over the next few years.

So, MarketAxess is one stock that I like this year and beyond.

Hill: To go back to Alphabet for a second, obviously the FAANG stocks have dominated

media coverage for so long.

It's interesting to see, with the pullback that we saw over the last couple of months,

a company like Amazon.

The focus is on, "They're down from their highs." Well, they are.

But over the past 12 months, it's a stock that's still up about 30%.

Whereas, in the case of Alphabet, Alphabet is basically flat from a year ago.

Cross: Yeah. The stock has basically trodden water.

That's one reason why it sells somewhere in the 15-18X earnings, when you think about

the amount of cash flow they generate and where they can put those investments into now.

They have to make money on those investments over the long-term.

I think they will. Again, it's a very large company. It's widely owned.

But I think that's a business that you can own and be comfortable with looking at the

next few years, regardless of what's going to happen to the stock market in the short-term.

For more infomation >> 2 Hot Stocks to Buy for 2019 - Duration: 3:48.

-------------------------------------------

Can Lawrence Culp Turn Around General Electric (GE) in 2019? - Duration: 7:37.

Chris Hill: Who were the CEOs you're watching?

Andy Cross: It seems like we talk about General Electric a lot on the show, but Lawrence Culp,

the new CEO at General Electric, is one that I'm really interested to watch.

They've gone through various CEOs over the last year.

A little bit of a surprise when the last CEO was kicked out after some of the initiatives

that he was making. We've talked about this on the show.

Larry Culp comes from Danaher here in D.C. That's a fabulous operator.

He ran that organization for more than 10 years and did really well.

He stepped down just to take some time away.

It'll be very interesting to see how he takes the reins at General Electric.

They're spinning off their digital business, they announced. I'm really interested to see.

This is a legendary business that has so struggled. At $70 billion, it's a company that's fallen from grace.

Someone with the talents of Larry Culp, to get the operating units going, their strength,

I'm interested to see if he can actually deliver on that.

Hill: A year ago at this time, one of the people we talked about was John Flannery,

who at the time was the CEO of General Electric.

I, among others, was praising Flannery for how clear he was being with Wall Street.

He was so open about, "This is what we're doing. There are no sacred cows at this company.

Everything is on the table."

And now, as you were talking, I thought to myself, "As clear as he was communicating

with Wall Street and with analysts, I wonder if, in hindsight, he maybe should have done

a little bit better job hand-holding the board of directors."

They couldn't fault him for being opaque. He was very clear. "This is what I'm going to do."

I was surprised when he got cut loose in the middle of the year.

Cross: We looked at General Electric earlier.

On one of our services, we shorted it a little bit when the stock was around $15. Now, it's around $8.

When you think about the challenge that Flannery had in front of him, and the way that he was

going about that, I thought, "This is a guy who has lots of success inside the General Electric family,

who could get this ship going in the right direction, making the changes

that people have been talking about for a while."

It just seems, like you said, the board wasn't behind that.

And at some point, when the last straw hit the camel's back, the board just didn't seem

to be aligned with where Flannery was taking the business or talking about taking the business.

They thought that was just a little bit too much for General Electric.

And they went towards Larry Culp, who's pretty new to the General Electric business.

Hill: I'm glad you used the phrase "the GE family" in reference to John Flannery,

because that's something to be noted about Larry Culp.

This is a guy coming from outside the company.

It's not to say that's either good or bad, but it is notable.

I think it's going to be very interesting to see what Culp does.

Cross: General Electric for years and years has talked about their management discipline,

going all the way back to Jack Welch, grooming these great managers.

I think we've seen over the last 10 years, that may not really be the best way to characterize that,

when you think about the long-term.

Or, maybe the business was just so dramatic and so big that it's hard to turn,

especially with the disaster the Financial business turned out to be.

Larry Culp comes from Danaher, where they have their Danaher business system.

That's an operating philosophy that's worked well for Danaher when it comes to acquiring businesses,

turning them into profit machines, reallocating that capital.

If that's the way that General Electric is going to go, and focusing on their core businesses,

that might be the way to get General Electric out of this deep rabbit hole that it's in right now.

Hill: If Larry Culp is not on the hot seat, let's just say it's a little warmer than the average CEO's.

Are there other CEOs that you look at and you think, "I'm keeping my eye on them,

I think they're poised for a great year."

Cross: The likes of a Larry Culp and Elon Musk, we love talking about those in the media

as they're struggling.

But there are definitely CEOs out there that are doing so well just from a day-to-day,

continue to grow that business. Mary Dillon at Ulta is one of those.

She's proven to be an exceptional CEO of that retailer of cosmetics.

The way that they add to their stores, renovate stores tactically, will shift their real estate.

How they have pushed the online business to be a bigger driver, how they have used their

membership rewards now to be able to drive so much more value on a per-member basis,

and make use of a footprint at a big box retailer that's fairly large.

In the face of the likes of Amazon and other retailers that are continuing to hunt at Ulta,

they have been able to continue to grow and grow pretty nicely.

It's exceptionally profitable for a retailer.

And, they use that capital very well and have very high returns on that capital.

Every dollar they're investing back in the business continues to become more and more valuable.

Mary Dillon does get some respect, but she's not a household name, and she should be.

Hill: Particularly when you consider that, for the stretch of time that she's been in

the corner office, you mentioned the salon business, Ulta was doing very well in that.

I'm sure there were at least a couple of people in her lieutenants who were like, "No, let's keep going here."

The decision to really push the online business was a smart one.

This was not a business that needed turnaround. This was a successful business.

And she was not in any way satisfied with that.

She said, "No, we can be doing more to grow this business."

Cross: That's very apropos, when you say she was not satisfied.

When she came in, she had the membership media experience from her previous roles.

She brought that, infused that into Ulta, used that as a new focal point for them to

be able to grow their sales per square foot from focusing on the more profitable members

tied to their membership business and using that as a catalyst to drive the online business, as well.

They've mastered that.

In some ways, that omni-channel presence has been able to keep the cosmetics competition

and retail competition at bay.

And, they've also been able to strike up really great partnerships with exclusive brands like

Kylie Jenner, as well.

That's been another way to keep Ulta front and center when it comes to their members

when they want to use, test, and buy cosmetics.

Không có nhận xét nào:

Đăng nhận xét